Handelsbanken Fonder AB Acquires 6,600 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Handelsbanken Fonder AB grew its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 24.6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 33,400 shares of the company’s stock after buying an additional 6,600 shares during the period. Handelsbanken Fonder AB’s holdings in Hims & Hers Health were worth $808,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Crewe Advisors LLC bought a new stake in Hims & Hers Health in the fourth quarter valued at about $28,000. Raleigh Capital Management Inc. increased its stake in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Hims & Hers Health in the 4th quarter valued at approximately $48,000. GAMMA Investing LLC boosted its stake in Hims & Hers Health by 2,173.7% during the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after acquiring an additional 2,152 shares during the last quarter. Finally, Principal Securities Inc. boosted its stake in Hims & Hers Health by 48.2% during the 4th quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock worth $74,000 after acquiring an additional 1,002 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, insider Michael Chi sold 17,303 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $48.14, for a total transaction of $832,966.42. Following the transaction, the insider now directly owns 193,601 shares in the company, valued at $9,319,952.14. The trade was a 8.20 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Soleil Boughton sold 4,152 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the sale, the insider now owns 157,345 shares of the company’s stock, valued at $9,549,268.05. This trade represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,097,578 shares of company stock valued at $38,080,320 in the last 90 days. 17.71% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

HIMS has been the topic of several analyst reports. Citigroup increased their target price on shares of Hims & Hers Health from $25.00 to $27.00 and gave the stock a “sell” rating in a report on Tuesday. Leerink Partners lifted their target price on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a report on Tuesday. Truist Financial increased their price target on Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a report on Wednesday. Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and an average price target of $37.23.

Hims & Hers Health Trading Up 9.3 %

Hims & Hers Health stock opened at $45.20 on Friday. The company has a fifty day simple moving average of $36.57 and a 200 day simple moving average of $26.66. Hims & Hers Health, Inc. has a 1-year low of $11.20 and a 1-year high of $72.98. The company has a market cap of $9.87 billion, a P/E ratio of 102.72 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.